Technical Description
This invention relates generally to pharmaceutical compositions for the treatment of skin cancers. The synergistic formulation comprises at least one beta caryophyllene and at least one aromadendrene oxide-2 in a ratio of about 2:1 by weight.
Problems Addressed
- Complex Method
- Toxicity
- Inefficient Formulations
- No Synergistic Compounds
- Side Effects
Tech Features
- Synergistic Composition
- Targeted Skin Cancer Treatment
- Effective & Curative
- Non-toxic
- Wide Range of Applications
Target Audience
- Healthcare & Medical Sector
- Pharmaceutical Industry
- Biotechnology Industry
- Oncology Treatment Centres
- Research & Development
Tech ID: P35-1740 TRL 4 Patent Status: Granted Available For Exclusive and Non-exclusive License
